Consensus Price Target Updates for Kadmon Holdings, Inc. (NYSE:KDMN) & Cellular Biomedicine Group Inc. (NASDAQ:CBMG)

Sell-side analysts are offering a consensus “Buy” rating on shares of Kadmon Holdings, Inc. (NYSE:KDMN).  Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 2.30.  Based on a recent trade, the shares are hovering around $4.23 which, according to analysts, yield significant upside potential to the $10.67 consensus target price.

At the time of writing, the stock was trading at $4.23. This represents a change from most recent open price of 9.87%. In terms of performance, year to date, the stock is 16.85%. The monthly stock performance comes in at 14.95%. For the quarter, shares are performing at 22.61%. Weekly performance analysis shows the equity at 13.71%.

In taking a look at technical levels, shares are trading 16.99% away from the 50 day simple moving average and 35.46% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -16.57% away from it’s 52- week high and 106.34% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Kadmon Holdings, Inc.’s RSI stands at 74.58. In looking at volatility levels, the shares saw weekly volatility of 6.58% and 4.89% over the past month.

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm.  The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 2.00.  This is according to all covering research brokerage firms taken into consideration by First Call.  The consensus price target of $18.00 also implies significant upside from the current price of $19.65.   

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) shares typically trade an average volume of 43.62 and institutions hold 4.00% of the total shares.  


We see here that the stock is 45.45% away from the 20-Day Simple Moving Average.  Their 50-Day Simple Moving Average is a difference of 66.72% from current levels.  Further back, their 200-Day Simple Moving Average is 98.02% difference from today’s price.  Currently, the stock is -12.28% from its 50-Day High and 100.51% from the 50-day low. 

Cellular Biomedicine Group Inc. (NASDAQ:CBMG)‘s stock has performed at 74.67%.  Breaking that down further, it has performed 9.17% for the week, 87.14% for the month, 96.50% over the last quarter, 128.49% for the past half-year and 48.30% for this last year. 

Leave a Comment